Who are Venlafaxine and Lamotrigine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/venlafaxine-and-lamotrigine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Venlafaxine and Lamotrigine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Venlafaxine and Lamotrigine (Venlafaxine and Lamotrigine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SNRI + anticonvulsant combination. Area: Psychiatry / Neurology.

marketed SNRI + anticonvulsant combination Serotonin transporter, norepinephrine transporter, voltage-gated sodium channels, glutamate modulation Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Venlafaxine and Lamotrigine (Venlafaxine and Lamotrigine) — University Health Network, Toronto. Venlafaxine inhibits reuptake of serotonin and norepinephrine while lamotrigine stabilizes neuronal membranes by blocking sodium channels and modulating glutamate release, together providing antidepressant and mood-stabilizing effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Venlafaxine and Lamotrigine TARGET	Venlafaxine and Lamotrigine	University Health Network, Toronto	marketed	SNRI + anticonvulsant combination	Serotonin transporter, norepinephrine transporter, voltage-gated sodium channels, glutamate modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SNRI + anticonvulsant combination class)

University Health Network, Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Venlafaxine and Lamotrigine — Competitive Intelligence Brief. https://druglandscape.com/ci/venlafaxine-and-lamotrigine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab